Adjuvant Carcinoma of the Colorectal
ECOG E5202
A Randomized, Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

CINJOG 070806
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX- Bevacizumab "No prior chemo for metastatic disease"

May have a history of prior malignancy provided there is NED & not on treatment including hormonal Therapy
Bevacizumab (IV) and Oxaliplatin (IV) – Day 1 of a 21 day cycle
Capecitabine D1-15
Hydroxychloroquine daily D1-21

ECOG N0147
Stage III Colon Cancer after Curative resection Phase III trial FOLFOX with or without Cetuximab